Effects of chronic administration of mergocryptine on changes in neurotransmitter levels in the ischemic gerbil brain

N. Ogawa, K. Haba, Masato Asanuma, M. Kawata, A. Mori

Research output: Contribution to journalArticle

Abstract

Changes in various neurotransmitter systems of the gerbil brain during ischemia and the effects of administration of mergocryptine, a new ergot derivative were studied. Gerbils intraperitoneally administered 0.5 mg/kg of mergocryptine or the vehicle once a day for 14 days were used. The administration of mergocryptine to control animals had no effect on the contents of neurotransmitters or their metabolites in various regions of the brain, but it corrected abnormalities in the neurotransmitter systems caused by ischemia. These results suggest the usefulness of mergocryptine against the deleterious effects of brain ischemia.

Original languageEnglish
Pages (from-to)21-31
Number of pages11
JournalArchives Internationales de Pharmacodynamie et de Therapie
Volume308
Publication statusPublished - 1990

Fingerprint

mergocriptine
Gerbillinae
Neurotransmitter Agents
Brain
Brain Ischemia
Ischemia

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{bafec55317d04e55af50f5be06489564,
title = "Effects of chronic administration of mergocryptine on changes in neurotransmitter levels in the ischemic gerbil brain",
abstract = "Changes in various neurotransmitter systems of the gerbil brain during ischemia and the effects of administration of mergocryptine, a new ergot derivative were studied. Gerbils intraperitoneally administered 0.5 mg/kg of mergocryptine or the vehicle once a day for 14 days were used. The administration of mergocryptine to control animals had no effect on the contents of neurotransmitters or their metabolites in various regions of the brain, but it corrected abnormalities in the neurotransmitter systems caused by ischemia. These results suggest the usefulness of mergocryptine against the deleterious effects of brain ischemia.",
author = "N. Ogawa and K. Haba and Masato Asanuma and M. Kawata and A. Mori",
year = "1990",
language = "English",
volume = "308",
pages = "21--31",
journal = "Archives Internationales de Pharmacodynamie et de Therapie",
issn = "0003-9780",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Effects of chronic administration of mergocryptine on changes in neurotransmitter levels in the ischemic gerbil brain

AU - Ogawa, N.

AU - Haba, K.

AU - Asanuma, Masato

AU - Kawata, M.

AU - Mori, A.

PY - 1990

Y1 - 1990

N2 - Changes in various neurotransmitter systems of the gerbil brain during ischemia and the effects of administration of mergocryptine, a new ergot derivative were studied. Gerbils intraperitoneally administered 0.5 mg/kg of mergocryptine or the vehicle once a day for 14 days were used. The administration of mergocryptine to control animals had no effect on the contents of neurotransmitters or their metabolites in various regions of the brain, but it corrected abnormalities in the neurotransmitter systems caused by ischemia. These results suggest the usefulness of mergocryptine against the deleterious effects of brain ischemia.

AB - Changes in various neurotransmitter systems of the gerbil brain during ischemia and the effects of administration of mergocryptine, a new ergot derivative were studied. Gerbils intraperitoneally administered 0.5 mg/kg of mergocryptine or the vehicle once a day for 14 days were used. The administration of mergocryptine to control animals had no effect on the contents of neurotransmitters or their metabolites in various regions of the brain, but it corrected abnormalities in the neurotransmitter systems caused by ischemia. These results suggest the usefulness of mergocryptine against the deleterious effects of brain ischemia.

UR - http://www.scopus.com/inward/record.url?scp=0025615639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025615639&partnerID=8YFLogxK

M3 - Article

VL - 308

SP - 21

EP - 31

JO - Archives Internationales de Pharmacodynamie et de Therapie

JF - Archives Internationales de Pharmacodynamie et de Therapie

SN - 0003-9780

ER -